Framework Journal · one stock, one dated entry

Recorded 2025-06-30 · Permanent

Propanc Biopharma Inc PPCB

Clears both ethical standards

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.

The label
Markdown

read at $1.49

Propanc Biopharma Inc holds its Markdown at $1.49.

PHINPOOPSC
  • PHPhase · the trend structure carries the Markdown label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · screen not yet scored
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2025-06-30
PhaseMarkdown · caution
Quantitative stateThe statistical read favours the sellers, held for 86 days
Price$1.49
Valuation0.00 trailing · N/A forward price to earnings
Values screenNot scored · score 70.0
Beta3.30

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Trailing P/E0.0x
very cheap relative to earnings
Profit margin0.0%
currently unprofitable
Return on equity-127.0%
not currently earning a positive return on equity
Debt to equity0.05
minimal debt — a conservative balance sheet
Current ratio2.37
comfortably covers its short-term bills
Beta3.30
much more volatile than the market
Market cap$3M
Employees1

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to Australia and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in PPCB's space worth a look

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 34.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 7%. Entered 2026-08-09 · Markdown

The dated journal · newest first, never edited

2026-08-09 Markdown $1.49 -34.4% Entry 4

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 34.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 7%.

2026-07-18 Markdown $2.27 +0.0% Entry 3

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 7%.

2026-07-03 Markdown $2.27 +0.0% Entry 2

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.

2026-07-02 Markdown $2.27 Entry 1

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $2.35 -42.2% · $578 -42.2%
2 months $2.58 -47.2% · $528 -47.2%
3 months $3.03 -55.0% · $450 -55.0%
6 months $20.17 -93.3% · $68 -93.3%
1 year $200.00 -99.3% · $7 -99.3%
2 years $0.08 +1,600.5% · $17,005 +1,600.5%
3 years $2.50 -45.6% · $544 -45.6%
5 years $3,150.00 -100.0% · $0 -100.0%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever PPCB does next, these words stay.

Propanc Biopharma Inc · PPCB · Markdown · $1.49
Recorded 2025-06-30 · before the outcome · scored mechanically

Get our weekly market brief free.